Abstract
Angiotensin receptor blockers (ARBs) are preferred antihypertensive therapies in patients with type 2 diabetes mellitus (T2DM). Azilsartan medoxomil (AZL-M) is a potent ARB for the treatment of stages 1-2 hypertension. We compared the efficacy, safety, and metabolic effects of AZL-M to both valsartan (VAL) and olmesartan (OLM), separately in patients with impaired fasting glucose (prediabetes mellitus) and T2DM. A pooled analysis of 3821 patients from three separate randomized placebo-controlled trials comparing the effects of AZL-M (40 and 80 mg), OLM (40 mg), VAL (320 mg), and placebo on changes in ambulatory and clinic blood pressure (BP) among patients with hypertension and prediabetes mellitus or T2DM was performed. Two analysis pools were created to facilitate comparisons: Pool A included patients who received placebo, AZL-M or OLM and Pool B included those who received AZL-M or VAL. Within each pool, patients were stratified by glycemic subgroups (normoglycemic, prediabetes mellitus, or T2DM) based on hemoglobin A1c values. Changes from baseline in both 24-h and clinic SBP were the primary efficacy assessments. Baseline 24-h mean SBPs were approximately 145 and 146 mmHg in the prediabetes mellitus and T2DM subgroups, res...Continue Reading
References
Jul 1, 1985·Diabetologia·D R MatthewsR C Turner
Jul 23, 1998·The New England Journal of Medicine·S M HaffnerM Laakso
Sep 11, 1998·BMJ : British Medical Journal
Aug 11, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Giuseppe DerosaRoberto Fogari
Jun 29, 2005·Archives of Internal Medicine·Fiona TurnbullUNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
May 9, 2007·American Journal of Hypertension·Masaru IwaiMasatsugu Horiuchi
Mar 25, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shiho NakayamaRyuzo Kawamori
Dec 5, 2008·The New England Journal of Medicine·Kenneth JamersonUNKNOWN ACCOMPLISH Trial Investigators
Aug 29, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shin-ichiro MasudaSatoshi Umemura
Jul 9, 2010·Lancet·UNKNOWN Emerging Risk Factors CollaborationJ Danesh
Dec 3, 2010·The Journal of Pharmacology and Experimental Therapeutics·Mami OjimaHideaki Nagaya
Jan 29, 2011·The Journal of Clinical Hypertension·George L BakrisStuart Kupfer
Feb 2, 2011·Hypertension·William B WhiteStuart Kupfer
Mar 16, 2011·Hypertension·Guanmin ChenNorm R C Campbell
Jul 19, 2011·The Journal of Clinical Hypertension·Domenic SicaStuart Kupfer
Oct 12, 2011·Journal of Hypertension·Takashi KajiyaTheodore W Kurtz
Jan 11, 2013·Endocrine Journal·Tadashi AraoYoshiya Tanaka
Sep 3, 2013·European Heart Journal·UNKNOWN Authors/Task Force MembersRobert G Xuereb
Dec 18, 2013·The Journal of Clinical Hypertension·Michael A WeberStephen B Harrap
Dec 20, 2013·JAMA : the Journal of the American Medical Association·Paul A JamesEduardo Ortiz
Jun 13, 2014·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Daniel Lorber
Feb 11, 2015·JAMA : the Journal of the American Medical Association·Connor A EmdinAnushka Patel
Citations
Aug 19, 2016·Frontiers in Pharmacology·Georgios GeorgiopoulosDimitrios Tousoulis
May 13, 2017·International Heart Journal·Yuhei ShigaKeijiro Saku
Jul 7, 2017·The Journal of Clinical Hypertension·Joel M NeutelAlison Handley
Mar 6, 2018·The Journal of Clinical Hypertension·George L BakrisSuzanne Oparil
Nov 21, 2017·Journal of the American Heart Association·Thomas M MacDonaldUNKNOWN British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm‐based Therapy (PATHWAY)
Feb 23, 2019·Diabetes, Obesity & Metabolism·Piero RuggenentiUNKNOWN VALID Study Organization
Jul 5, 2018·Irish Journal of Medical Science·Di ZhaoPingshuan Dong
Dec 13, 2019·International Journal of Hypertension·Dae Wook LeePhilippe Pinton
Jan 7, 2017·Cardiovascular Diabetology·Alon Grossman, Ehud Grossman
Aug 23, 2019·Current Drug Targets·Khuraijam Dhanachandra Singh, Sadashiva S Karnik
Oct 30, 2020·Current Medical Research and Opinion·Irina E Chazova, Yulia V Zhernakova
Jul 1, 2020·Clinical Therapeutics·Ami Kwon, Gee-Hee Kim
Jul 13, 2021·Cardiology Clinics·Luke J Laffin, George L Bakris